Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells

Cancer Biology and Therapy

Volumn 7, Issue 10, 2008, Pages 1685-1693

  Stepulak, Andrzej ^a,b   Rzeski, Wojciech ^c,d   Sifringer, Marco ^e   Brocke, Katja ^a   Gratopp, Alexander ^e   Kupisz, Krzysztof ^f   Turski, Lechoslaw ^g   Ikonomidou, Chrysanthy ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^d INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^e HUMBOLDT UNIVERSITY   (Germany)

^f Jan Bozy District Hospital   (Poland)

^g Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Cancer; Cell cycle; ERK1 2 pathway; Fluoxetine; Signal transduction

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; FLUOXETINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C JUN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MEDULLOBLASTOMA; NEUROBLASTOMA; ONCOGENE C FOS; ONCOGENE C MYC; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TIMED DRUG RELEASE;

EID: 54349101785     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.10.6664     Document Type: Article

References (52)

1. Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 2005; 162:835-8.
2. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. Jama 2002; 287:203-9.
3. Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61:81-110.
4. Garcia-Colunga J, Awad JN, Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 1997; 94:2041-4.
5. Ranganathan R, Sawin ER, Trent C, Horvitz HR. Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine. J Neurosci 2001; 21:5871-84.
6. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71:533-54.
7. Grewal JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL. Serotonin 5-HT2A receptor induces TGFbeta1 expression in mesangial cells via ERK: proliferative and fibrotic signals. Am J Physiol 1999; 276:922-30.
8. Nebigil CG, Etienne N, Messaddeq N, Maroteaux L. Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B receptor signaling. Faseb J 2003; 17:1373-5.
9. Seuwen K, Pouyssegur J. Serotonin as a growth factor. Biochem Pharmacol 1990; 39:985-90.
10. Aune TM, McGrath KM, Sarr T, Bombara MP, Kelley KA. Expression of 5HT1a receptors on activated human T cells. Regulation of cyclic AMP levels and T cell proliferation by 5-hydroxytryptamine. J Immunol 1993; 151:1175-83.
11. Matsusaka S, Wakabayashi I. 5-Hydroxytryptamine as a potent migration enhancer of human aortic endothelial cells. FEBS Lett 2005; 579:6721-5.
12. Cattaneo MG, Fesce R, Vicentini LM. Mitogenic effect of serotonin in human small cell lung carcinoma cells via both 5-HT1A and 5-HT1D receptors. Eur J Pharmacol 1995; 291:209-11.
13. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004; 59:328-36.
14. Ishizuka J, Beauchamp RD, Townsend CM Jr, Greeley GH Jr, Thompson JC. Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol 1992; 150:1-7.
15. Vicaut E, Laemmel E, Stucker O. Impact of serotonin on tumour growth. Ann Med 2000; 32:187-94.
16. Garnovskaya MN, van Biesen T, Hawe B, Casanas Ramos S, Lefkowitz RJ, Raymond JR. Ras-dependent activation of fibroblast mitogen-activated protein kinase by 5-HT1A receptor via a G protein beta gamma-subunit-initiated pathway. Biochemistry 1996; 35:13716-22.
17. Julius D. Molecular biology of serotonin receptors. Annu Rev Neurosci 1991; 14:335-60.
18. Launay JM, Birraux G, Bondoux D, Callebert J, Choi DS, Loric S, Maroteaux L. Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem 1996; 271:3141-7.
19. Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 1988; 335:254-6.
20. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 1995; 154:247-50.
21. Dizeyi N, Bjartell A, Hedlund P, Tasken KA, Gadaleanu V, Abrahamsson PA. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol 2005; 47:895-900.
22. Julius D, Livelli TJ, Jessell TM, Axel R. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science 1989; 244:1057-62.
23. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24:21-44.
24. Cloez-Tayarani I, Kayyali US, Fanburg BL, Cavaillon JM. 5-HT activates ERK MAP kinase in cultured-human peripheral blood mononuclear cells via 5-HT1A receptors. Life Sci 2004; 76:429-43.
25. Leone AM, Errico M, Lin SL, Cowen DS. Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT(1B) receptors in transfected BE(2)-C neuroblastoma cells is inhibited by RGS4. J Neurochem 2000; 75:934-8.
26. Watts SW. Activation of the mitogen-activated protein kinase pathway via the 5-HT2A receptor. Ann N Y Acad Sci 1998; 861:162-8.
27. Watts SW, Yang P, Banes AK, Baez M. Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors. J Cardiovasc Pharmacol 2001; 38:539-51.
28. Greene EL, Houghton O, Collinsworth G, Garnovskaya MN, Nagai T, Sajjad T, Bheemanathini V, Grewal JS, Paul RV, Raymond JR. 5-HT(2A) receptors stimulate mitogen-activated protein kinase via H(2)O(2) generation in rat renal mesangial cells. Am J Physiol Renal Physiol 2000; 278:650-8.
29. Quinn JC, Johnson-Farley NN, Yoon J, Cowen DS. Activation of extracellular-regulated kinase by 5-hydroxytryptamine(2A) receptors in PC12 cells is protein kinase C-independent and requires calmodulin and tyrosine kinases. J Pharmacol Exp Ther 2002; 303:746-52.
30. Werry TD, Gregory KJ, Sexton PM, Christopoulos A. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem 2005; 93:1603-15.
31. Lin SL, Johnson-Farley NN, Lubinsky DR, Cowen DS. Coupling of neuronal 5-HT7 receptors to activation of extracellular-regulated kinase through a protein kinase A-independent pathway that can utilize Epac. J Neurochem 2003; 87:1076-85.
32. Norum JH, Methi T, Mattingly RR, Levy FO. Endogenous expression and protein kinase A-dependent phosphorylation of the guanine nucleotide exchange factor Ras-GRF1 in human embryonic kidney 293 cells. Febs J 2005; 272:2304-16.
33. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17:1263-93.
34. Xing J, Ginty DD, Greenberg ME. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996; 273:959-63.
35. Fumagalli F, Molteni R, Calabrese F, Frasca A, Racagni G, Riva MA. Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. J Neurochem 2005; 93:1551-60.
36. Ha E, Jung KH, Choe BK, Bae JH, Shin DH, Yim SV, Baik HH. Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci Lett 2006; 397:185-9.
37. Mercier G, Lennon AM, Renouf B, Dessouroux A, Ramauge M, Courtin F, Pierre M. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004; 24:207-16.
38. Arimochi H, Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 2006; 541:17-23.
39. Yue CT, Liu YL. Fluoxetine increases extracellular levels of 3-methoxy-4-hydroxyphenylglycol in cultured COLO320 DM cells. Cell Biochem Funct 2005; 23:109-14.
40. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, Bunce CM, Gregory CD, Barnes NM, Gordon J. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 2003; 101:3212-9.
41. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci 2005; 27:29-42.
42. Database TMTG. http://www.myc-cancer-gene.org/site/mycTargetDB.asp.
43. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL, Hogg GR, Warrington RC, Fang W, LaBella FS. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992; 52:3796-800.
44. Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ. Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Ther Oncol 2003; 3:169-84.
45. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20:2390-400.
46. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1, NFkappaB and Pdcd4. Trends Mol Med 2003; 9:36-41.
47. Petty WJ, Dragnev KH, Dmitrovsky E. Cyclin D1 as a target for chemoprevention. Lung Cancer 2003; 41:155-61.
48. Stoll AL, Pope HG Jr, McElroy SL. High-dose fluoxetine: safety and efficacy in 27 cases. J Clin Psychopharmacol 1991; 11:225-6.
49. Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999; 48:521-7.
50. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000; 23:428-38.
51. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5:322-9.
52. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59:42-8.